
A survey by Neurocrine Biosciences reveals that about 20% of working adults with tardive dyskinesia (TD) quit their jobs due to untreated involuntary movements, missing an average of 8 hours of work or school weekly before treatment. The findings highlight the significant impact of TD on employment and daily life, emphasizing the need for early diagnosis and appropriate treatment. Despite guidelines recommending FDA-approved VMAT2 inhibitors for moderate to severe TD, only 10% receive such treatment. The survey underscores the importance of awareness during Tardive Dyskinesia Awareness Week to improve screening and management of this condition affecting over 800,000 U.S. adults.